Search

Your search keyword '"Xu, Jian-Ming"' showing total 350 results
Start Over Author "Xu, Jian-Ming" Publication Type Academic Journals
350 results on '"Xu, Jian-Ming"'

18. The Quasi-Boundary Regularization Method for Recovering the Initial Value in a Nonlinear Time–Space Fractional Diffusion Equation.

Author

Li, Dun-Gang, Chen, Yong-Gang, Gao, Yin-Xia, Yang, Fan, Xu, Jian-Ming, and Li, Xiao-Xiao

Subjects
BURGERS' equation, INITIAL value problems, INVERSE problems, HEAT equation
Abstract

In this paper, we consider the inverse problem for identifying the initial value problem of the time–space fractional nonlinear diffusion equation. The uniqueness of the solution is proved by taking the fixed point theorem of Banach compression, and the ill-posedness of the problem is analyzed through the exact solution. The quasi-boundary regularization method is chosen to solve the ill-posed problem, and the error estimate between the regularization solution and the exact solution is given. Moreover, several numerical examples are chosen to prove the effectiveness of the quasi-boundary regularization method. Finally, our method can be used to solve high dimensional time–space fractional nonlinear diffusion equation, especially in cylindrical and spherical symmetric regions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms.

Author

Jia, Ru, Li, Yi, Xu, Nong, Jiang, Hai-Ping, Zhao, Chuan-Hua, Liu, Rong-Rui, Shi, Yue, Zhang, Yao-Yue, Wang, Shu-Yan, Zhou, Hui, and Xu, Jian-Ming

Subjects
METASTASIS, MONOCLONAL antibodies, INVESTIGATIONAL drugs, NEUROENDOCRINE tumors, LONGITUDINAL method
Abstract

Background Neuroendocrine neoplasms (NENs) are a group of diseases that show high heterogeneity but have limited treatment options. This phase I study evaluated the safety and efficacy of sintilimab, anti-PD-1 monoclonal antibody, in treating advanced NENs. Methods We prospectively enrolled patients pathologically diagnosed with NENs after standard treatment failure. Neuroendocrine neoplasms were classified into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine cancers (NECs). Every patient received sintilimab, and response was assessed every 9 weeks. Results Twenty-four patients with a median age of 57.0 years were enrolled from November 2016 to 2017. The median Ki-67 index was 60%. Five patients had NET, 1 had NET G3, 17 had NEC, and 1 had mixed adenocarcinoma-neuroendocrine carcinoma. The most common primary tumor sites were the pancreas and gastrointestinal tract in 7 and 10 patients, respectively. In phase Ia trial, 2 patients received sintilimab 1 mg/kg every 2 weeks, one received 3 mg/kg every 2 weeks, and 21 patients enrolled in the phase Ib trial received 200 mg every 3 weeks. The objective response rate was 20.8% in all enrolled patients and 27.8% in NEC patients. The median progression-free survival was 2.2 and 2.1 months in patients with NET and NEC, respectively. The median OS was not applicable (NA) and 10.8 months (95% CI, 4.3, NA) with NET and NEC, respectively. The duration of response (DOR) was not reached, with a median follow-up time of 20.7 months. Treatment-related adverse events (TRAE) occurred in 17 (70.8%) patients. The most frequent TRAE was thyroid dysfunction (41.7%), and a grade 3 pulmonary infection occurred in 1 patient. The programmed cell death 1-ligand 1 (PD-L1)-positive (tumor proportion score ≥1%) rate was 18.8% (3 out of 16) and the expression of PD-L1 did not correlate with response. Conclusion Sintilimab was well-tolerated and showed encouraging response in NECs. ClinicalTrials.gov Identifier NCT02937116. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results